Karyopharm Therapeutics (KPTI) Amortizatization of Intangibles (2015 - 2025)
Karyopharm Therapeutics (KPTI) reported Amortizatization of Intangibles of $9000.0 for Q4 2025, down 97.7% on a YoY basis from $392000.0 in Q4 2024, and down 80.0% quarter-over-quarter from $45000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Amortizatization of Intangibles (2015 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Amortizatization of Intangibles for 11 years, with the latest figure at $9000.0 in Q4 2025.
- For the quarter ending Q4 2025, Amortizatization of Intangibles fell 97.7% year-over-year to $9000.0; the trailing twelve-month figure through Dec 2025 stood at $410000.0 (down 83.63% YoY), and the FY2025 full-year result was $410000.0, down 83.63% from the prior year.
- Amortizatization of Intangibles for Q4 2025 stood at $9000.0, down from $45000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $1.1 million in Q1 2023, with the low at -$664000.0 in Q1 2021.
- Historically, Amortizatization of Intangibles has averaged $313850.0 across 5 years, with a median of $263000.0 in 2022.
- Annual changes were most pronounced in 2021 — Amortizatization of Intangibles slumped 5433.33% — and 2023, when it soared 2602.22%.
- Karyopharm Therapeutics' Amortizatization of Intangibles stood at -$138000.0 in 2021, then surged by 436.23% to $464000.0 in 2022, then soared by 120.04% to $1.0 million in 2023, then tumbled by 61.61% to $392000.0 in 2024, then tumbled by 97.7% to $9000.0 in 2025.
- The last three Amortizatization of Intangibles figures came in at $9000.0 (Q4 2025), $45000.0 (Q3 2025), and $120000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | 9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 45,000.00 |
| Sep 30, 2025 | 45,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | 236,000.00 |
| Mar 31, 2025 | 236,000.00 |
| Dec 31, 2024 | 392,000.00 |
| Dec 31, 2024 | 392,000.00 |
| Sep 30, 2024 | 531,000.00 |
| Sep 30, 2024 | 531,000.00 |
| Jun 30, 2024 | 670,000.00 |
| Jun 30, 2024 | 670,000.00 |
| Mar 31, 2024 | 911,000.00 |
| Mar 31, 2024 | 911,000.00 |
| Dec 31, 2023 | 1.02 Mn |
| Dec 31, 2023 | 1.02 Mn |
| Sep 30, 2023 | 936,000.00 |
| Sep 30, 2023 | 936,000.00 |